Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor

Details Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor

2006-03-21

2006-03-21

Davis, Zinna Northington (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S310000, C514S403000, C546S143000, C546S199000, C548S362100

Reexamination Certificate

active

07015233

ABSTRACT:
Compounds of formula (I)are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

REFERENCES:
patent: 5656634 (1997-08-01), Chang et al.
patent: 6001860 (1999-12-01), Hamanaka
patent: 587180 (1994-03-01), None
patent: 1256574 (2002-11-01), None
patent: WO 98/50347 (1998-12-01), None
patent: 03/055484 (2003-07-01), None
patent: 03/055848 (2003-07-01), None
Berge et al., J. Pharmaceutical Sciences 66:1 et seq. (1977).
Caterina et al., “Impaired nociception and pain sensation in mice lacking the capsaicin receptor,” Science 288:306-313 (2000).
Caterina et al., “The capsaicin receptor: a heat-activated ion channel in the pain pathway,” Nature 389:816-824 (Oct. 23, 1997).
Caterina et al., “The vanilloid receptor: a molecular gateway to the pain pathway,” Annu. Rev. Neurosci. 24:487-517 (2001).
Collier et al., “The abdominal constriction response and its suppression by analgesic drugs in the mouse,” Br. J. Pharmacol. Chemother. 32:295-310 (1968).
Davis et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia,” Nature 405:183-186 (2000).
Fowler, “Intravesical treatment of overactive bladder,” Urology 55(Supplement 5A):60-64 (2000).
Hayes et al., “Cloning and functional expression of a human orthologue or rat vanilloid receptor-1”, Pain 88:205-215 (2000).
IUPAC 1974 Recommendation for Sction E, Fundamental Sterochemistry, Pure App. Chem. 45:13-30 (1976).
Nolano et al., “Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation,” Pain 81:135-145 (1999).
Poste, et al., Prescott (Ed.) Methods in Cell Biology, Academic Press, New York, N.Y. vol. XIV:33 et seq. (1976).

Affiliated with

Also associated with

Rating

Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3603380